Spots Global Cancer Trial Database for P53 in Differentiated Thyroid Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: P53 in Differentiated Thyroid Cancer

Official Title: P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?

Study ID: NCT01954134

Conditions

Thyroid Neoplasms

Interventions

Study Description

Brief Summary: In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

Detailed Description: In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.